PTPN11 and systemic lupus erythematosus: With regards to SHP-2, SHP-2 activity is higher in PBMCs from patients with SLE than from healthy individuals, and SHP-2 inhibition has been shown to significantly reduce T cell proliferation and production of IFNγ and IL-17 (Wang J. et al., 2016).